Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10556943 HLA-DR binding peptides and their uses

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

February 11, 2020

Patent Application Number

15381454

Date Filed

December 16, 2016

Patent Citations Received

US Patent 12091443 Method of compact peptide vaccines using residue optimization

0

US Patent 11464842 Compositions and method for optimized peptide vaccines using residue optimization

US Patent 11981923 Pepmixes to generate multiviral CTLS with broad specificity

0

US Patent 12064475 Compositions and method for optimized peptide vaccines using residue optimization

0

US Patent 11464837 Immunogenic compositions comprising nucleic acids for RAS peptides

US Patent 11235039 Immunogenic compositions comprising nucleic acids for RAS peptides

US Patent 11672850 Compositions and method for optimized peptide vaccines using residue optimization

0

US Patent 11673936 Method of compact peptide vaccines using residue optimization

0

...

Patent Primary Examiner

Michael Szperka

Patent abstract

The present invention provides HLA-DR (MHC class II) binding peptides derived from the ovarian/breast cancer associated antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be used in cancer vaccines.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10556943 HLA-DR binding peptides and their uses

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool